- Home
- GLSI
as 01-17-2025 4:00pm EST
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | STAFFORD |
| Market Cap: | 143.4M | IPO Year: | 2020 |
| Target Price: | $38.00 | AVG Volume (30 days): | 43.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.00 - $21.44 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Greenwich LifeSciences Inc. (GLSI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Patel Snehal | GLSI | CEO and CFO | Jan 10 '25 | Buy | $12.51 | 2,500 | $31,275.00 | 5,552,502 | |
| Patel Snehal | GLSI | CEO and CFO | Jan 2 '25 | Buy | $11.97 | 2,000 | $23,940.00 | 5,552,502 | |
| Patel Snehal | GLSI | CEO and CFO | Dec 31 '24 | Buy | $11.36 | 2,400 | $27,264.00 | 5,552,502 | |
| Patel Snehal | GLSI | CEO and CFO | Dec 30 '24 | Buy | $11.12 | 3,200 | $35,584.00 | 5,552,502 | |
| Thompson Jaye | GLSI | VP Clinical Reg Affairs | Nov 21 '24 | Buy | $12.91 | 1,000 | $12,910.00 | 264,148 |
Latest Greenwich LifeSciences Inc. News
GLSI Breaking Stock News: Dive into GLSI Ticker-Specific Updates for Smart Investing
Argus Research
2 days ago
Daily – Vickers Top Insider Picks for 01/17/2025
Argus Research
3 days ago
Daily – Vickers Top Insider Picks for 01/16/2025
Argus Research
4 days ago
Daily – Vickers Top Insider Picks for 01/15/2025
Argus Research
5 days ago
Daily – Vickers Top Buyers & Sellers for 01/14/2025
Argus Research
5 days ago
Daily – Vickers Top Insider Picks for 01/14/2025
Argus Research
5 days ago
Daily – Vickers Top Buyers & Sellers for 01/14/2025
GlobeNewswire
5 days ago
Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01
MT Newswires
6 days ago
Greenwich LifeSciences Partners With Unicancer to Activate Sites for Breast Cancer Study in France
Compare GLSI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GLSI Greenwich LifeSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.